Search

Your search keyword '"van de Ven M"' showing total 431 results
Start Over Author "van de Ven M"
431 results on '"van de Ven M"'

3. Early Reading Intervention by Means of a Multicomponent Reading Game

Author

van de Ven, M., de Leeuw, L., van Weerdenburg, M., and Steenbeek-Planting, E. G.

Abstract

This study examined the effects of an intervention with a multicomponent reading game on the development of reading skills in 60 Dutch primary school children with special educational needs. The game contains evidence-based reading exercises and is based on principles of applied gaming. Using a multiple baseline approach, we tested children's word, pseudoword and text reading fluency, as well as their reading motivation, at three test occasions. The results indicated that the short intervention (9 × 15 min) enhanced children's pseudoword reading fluency as well as their text reading fluency. Interestingly, the early intervention group showed a sustained intervention effect (i.e., also during retention), which shows that using this reading game has a long-term effect on early text reading development. Intervention did not affect reading motivation, which suggests that the multicomponent reading game can be used to facilitate early reading development without compromising reading motivation.

Published
2017
Full Text
View/download PDF

4. Immunotherapy: TARGETING OVARIAN CARCINOMA WITH GDT002, A FIRST-IN-CLASS γδTCR-BASED T CELL THERAPY

Author

Middendorp, S., primary, Drent, E., additional, Bisso, A., additional, Baardman, S., additional, Verweij, D., additional, Salcedo, E., additional, Coomans, C., additional, Braem, S., additional, van de Weg, S., additional, Meijer, M., additional, Proost, N., additional, van de Ven, M., additional, Norell, H., additional, van Loenen, M., additional, Emami, N., additional, Melief, S., additional, Gobessi, S., additional, and Throsby, M., additional

Published
2023
Full Text
View/download PDF

5. Veiliger vervoer van gevaarlijke stoffen door te leren van incidenten. Onderzoek naar ervaringen van veiligheidsadviseurs met het leren van (bijna-)incidenten met vervoer van gevaarlijke stoffen

Author

Zonneveld, M, Fikke, R, van Kampen, J, and van de Ven, M

Subjects
RIVM rapport 2023-0211
Abstract

Er kunnen ongelukken of bijna-ongelukken gebeuren als gevaarlijke stoffen worden vervoerd over het spoor, wegen of binnenwater. Dit kan gevolgen hebben voor het milieu, het bedrijf dat erbij betrokken is, medewerkers en mensen in de omgeving. Het is daarom belangrijk om deze ongelukken zo veel mogelijk te voorkomen. Dat kan door beter te leren van ongelukken en bijna-ongelukken met dit type vervoer. Er bestaat hiervoor een leerprocesmodel van melden, onderzoeken, acties benoemen, communiceren en evalueren. Het RIVM heeft met veiligheidsadviseurs in kaart gebracht hoe bedrijven hiermee omgaan. Het blijkt dat veel bedrijven wel bezig zijn met leren van ongelukken en bijna-ongelukken, maar niet altijd het hele leerproces doorlopen. Om effectief van (bijna-)ongelukken te kunnen leren, is het belangrijk dat wel helemaal te doen. Ook kunnen veel bedrijven meer leren van bijnaongelukken. Verder is het belangrijk dat veiligheidsadviseurs leren van elkaars ervaringen door knelpunten en oplossingen met elkaar te delen. Een voorbeeld van een knelpunt is dat bedrijven een bijna-ongeluk niet altijd melden, omdat ze dat niet nuttig vinden. Een ander knelpunt is dat bedrijven niet evalueren of acties effectief zijn, omdat ze dat moeilijk kunnen beoordelen. Veel knelpunten kunnen worden opgelost door te horen hoe andere veiligheidsadviseurs ermee omgaan. Dat geldt niet voor alle knelpunten. Daarom noemen veiligheidsadviseurs ook een aantal verbeterpunten. Voorbeelden zijn meer aandacht voor leren van incidenten tijdens de opleiding tot veiligheidsadviseur. En stimuleren dat bedrijven die bij het vervoer samenwerken, vaker met elkaar het gesprek aangaan over veiligheid. De Vereniging van Veiligheidsadviseurs (VVA), brancheverenigingen en de overheid kunnen het gesprek over knelpunten en oplossingen faciliteren. Deze partijen zouden ook met elkaar in gesprek moeten gaan over de taken van veiligheidsadviseur bij het leren van incidenten. In de praktijk vullen veiligheidsadviseurs hun taak bij het leren van ongelukken anders in. Dat heeft bijvoorbeeld te maken met de grootte van het bedrijf en de tijd die ervoor is. Dit onderzoek is in opdracht van het ministerie van Infrastructuur en Waterstaat (IenW(Infrastructuur en Waterstaat)) uitgevoerd.

Published
2023

6. Anti-IL-5/5Ra biologics improve work productivity and activity in severe asthma: a RAPSODI registry-based cohort study

Author

van der Valk, J. P. M., Hekking, P. P., Rauh, S. P., Patberg, K. W., van Veen, I. A., Van Huisstede, A., Smeenk, F. W. J. M., van de Ven, M. J. T., Broeders, M. E. A. C., Hilvering, B., van Exsel, J., Oud, K. T. M., Langeveld, B., Fieten, K. B., van Veen, A., Hashimoto, S., Sont, J. K., Brinke, A. ten, Braunstahl, G. J., and Pulmonary Medicine

Abstract

Introduction: Severe asthma is associated with a serious disease burden, partially caused by limitations in activity and work impairment. Aims and objectives: This study aims to relate treatment with biologics targeting IL-5/5Ra to work productivity and activity in the long term in a real-world context. Material and methods: This is a registry-based multi-center cohort study evaluating data from adults with severe eosinophilic asthma included in the Dutch Register of Adult Patients with Severe Asthma for Optimal DIsease management (RAPSODI). Patients that started with anti-IL-5/5Ra biologics and completed the work productivity and activity improvement questionnaire, were included. Study and patient characteristics were compared between the employed and unemployed patients. Work productivity and activity impairment are related to accompanying improvements in clinical outcomes. Results: At baseline, 91 of 137 patients (66%) were employed which remained stable throughout the follow-up period. Patients in the working age category were younger and had significantly better asthma control (p = 0.02). Mean overall work impairment due to health decreased significantly from 25.5% (SD2.6) to 17.6% (SD 2.8) during 12 months anti-IL-5/5Ra biologics treatment (P = 0.010). There was a significant association between ACQ6 and overall work improvement after targeted therapy (β = 8.7, CI 2.1–15.4, P = 0.01). The improvement of asthma control of 0.5 points on the asthma Control Questionnaire was associated with an overall work impairment of −9%. Conclusions: Work productivity and activity in severe eosinophilic asthma improved after starting anti-IL-5/5Ra biologics. Clinically relevant improvement in asthma control was associated with an overall work impairment score of −9% in this study.

Published
2023

7. Factors Promoting Mental Health of Adolescents Who Have a Parent with Mental Illness: A Longitudinal Study

Author

Van Loon, L. M. A., Van De Ven, M. O. M., and Van Doesum, K. T. M.

Abstract

Background: Children of parents with mental illness have an elevated risk of developing a range of mental health and psychosocial problems. Yet many of these children remain mentally healthy. Objective: The present study aimed to get insight into factors that protect these children from developing internalizing and externalizing problems. Methods: Several possible individual, parent-child, and family protective factors were examined cross-sectionally and longitudinally in a sample of 112 adolescents. A control group of 122 adolescents whose parents have no mental illness was included to explore whether the protective factors were different between adolescents with and without a parent with mental illness. Results: Cross-sectional analyses revealed that high self-esteem and low use of passive coping strategies were related to fewer internalizing and externalizing problems. Greater self-disclosure was related to fewer internalizing problems and more parental monitoring was related to fewer externalizing problems. Active coping strategies, parental support, and family factors such as cohesion were unrelated to adolescent problem behavior. Longitudinal analyses showed that active coping, parental monitoring, and self-disclosure were protective against developing internalizing problems 2 years later. We found no protective factors for externalizing problems. Moderation analyses showed that the relationships between possible protective factors and adolescent problem behavior were not different for adolescents with and without a parent with mental illness. Conclusions: The findings suggest that adolescents' active coping strategies and parent-child communication may be promising factors to focus on in interventions aimed at preventing the development of internalizing problems by adolescents who have a parent with mental illness.

Published
2015
Full Text
View/download PDF

9. MULTIFREQUENCY CROSS‐CORRELATION PHASE FLUOROMETRY OF CHLOROPHYLL a FLUORESCENCE IN THYLAKOID AND PSII‐ENRICHED MEMBRANES

Author

Covindjee, Van de Ven, M, Cao, J, Roye, C, and Gratton, E

Subjects
Plant Biology, Biological Sciences, Physical Sciences, Chlorophyll, Chlorophyll A, Fabaceae, Fluorescence, Fluorometry, In Vitro Techniques, Intracellular Membranes, Light-Harvesting Protein Complexes, Oxidation-Reduction, Photosynthetic Reaction Center Complex Proteins, Photosystem II Protein Complex, Plants, Medicinal, Chemical Sciences, Biophysics, Biological sciences, Chemical sciences, Physical sciences
Abstract

We present here a comparative study on the decay of chlorophyll (Chl) a fluorescence yield in thylakoid membranes and photosystem II (PSII)-enriched samples, measured with multifrequency cross-correlation phase fluorometry. These measurements confirm the general conclusions of Van Mieghem et al. (Biochim. Biophys. Acta 1100, 198-206, 1992), obtained with a flash method, on the effects of reduction of the primary quinone acceptor (QA) on Chl a fluorescence yield of PSII. Different states of the reaction centers of PSII were produced by: (1) pretreatment with sodium dithionite and methyl viologen followed by laser illumination: the doubly reduced QA (QAH2) centers; (2) with laser illumination or pretreatment with diuron: QA- centers; and (3) the addition of micromolar concentration of dichlorobenzoquinone (DCBQ): oxidized QA centers. The data were analyzed with Lorentzian distribution as well as with multiexponential fluorescence decay functions. The analysis with Lorentzian distribution function showed that upon formation of QA-, the major lifetime distribution peak shifted to longer lifetimes: from 0.25 ns to 1.66 ns (pea thylakoid membranes) and from 0.24 ns to 1.31 ns (core PSII). However, when QAH2 was formed, the lifetime distribution peaks shifted back to shorter lifetimes (0.57-0.77 ns) both in thylakoids and PSII membranes. Multiexponential analysis showed three lifetime components: fast (40-400 ps), middle (300-1500 ps) and slow (5-25 ns). When QA- was formed in PSII centers, the amplitude of the fast component decreased, but both the amplitude and the lifetime of the middle component increased severalfold.(ABSTRACT TRUNCATED AT 250 WORDS)

Published
1993

10. Multifrequency cross-correlation phase fluorometry of chlorophyll a fluorescence in thylakoid and PSII-enriched membranes.

Author

Govindjee, Van de Ven, M, Cao, J, Royer, C, and Gratton, E

Subjects
Intracellular Membranes, Fabaceae, Plants, Medicinal, Chlorophyll, Light-Harvesting Protein Complexes, Photosystem II Protein Complex, Photosynthetic Reaction Center Complex Proteins, Fluorometry, Oxidation-Reduction, Fluorescence, In Vitro Techniques, Chlorophyll A, Plants, Medicinal, Biophysics, Physical Sciences, Chemical Sciences, Biological Sciences
Abstract

We present here a comparative study on the decay of chlorophyll (Chl) a fluorescence yield in thylakoid membranes and photosystem II (PSII)-enriched samples, measured with multifrequency cross-correlation phase fluorometry. These measurements confirm the general conclusions of Van Mieghem et al. (Biochim. Biophys. Acta 1100, 198-206, 1992), obtained with a flash method, on the effects of reduction of the primary quinone acceptor (QA) on Chl a fluorescence yield of PSII. Different states of the reaction centers of PSII were produced by: (1) pretreatment with sodium dithionite and methyl viologen followed by laser illumination: the doubly reduced QA (QAH2) centers; (2) with laser illumination or pretreatment with diuron: QA- centers; and (3) the addition of micromolar concentration of dichlorobenzoquinone (DCBQ): oxidized QA centers. The data were analyzed with Lorentzian distribution as well as with multiexponential fluorescence decay functions. The analysis with Lorentzian distribution function showed that upon formation of QA-, the major lifetime distribution peak shifted to longer lifetimes: from 0.25 ns to 1.66 ns (pea thylakoid membranes) and from 0.24 ns to 1.31 ns (core PSII). However, when QAH2 was formed, the lifetime distribution peaks shifted back to shorter lifetimes (0.57-0.77 ns) both in thylakoids and PSII membranes. Multiexponential analysis showed three lifetime components: fast (40-400 ps), middle (300-1500 ps) and slow (5-25 ns). When QA- was formed in PSII centers, the amplitude of the fast component decreased, but both the amplitude and the lifetime of the middle component increased severalfold.(ABSTRACT TRUNCATED AT 250 WORDS)

Published
1993

16. Chlorophyll a fluorescence lifetime distributions in open and closed Photosystem II reaction center preparations

Author

Govindjee, van de Ven, M, Preston, C, Seibert, M, and Gratton, E

Subjects
Physical Sciences, Chlorophyll, Cytochrome b Group, Light-Harvesting Protein Complexes, Photosynthesis, Photosynthetic Reaction Center Complex Proteins, Photosystem II Protein Complex, Plant Proteins, Plants, Spectrometry, Fluorescence, Biological Sciences, Biological sciences, Physical sciences
Abstract

We have measured the decay of chlorophyll a fluorescence at 4 degrees C under anaerobic conditions in stabilized photosystem II reaction center complex isolated from spinach, using multifrequency (2-400 MHz) cross-correlation phase fluorometry. Examination of our data shows that although the fluorescence decay of open reaction centers (i.e., when both the electron donor P-680 and the electron acceptor pheophytin are capable of engaging in charge separation) can be analyzed as a multiexponential decay, another representation of the data is obtained when the decay is analyzed using a continuous distribution of lifetimes. Our results on the open reaction center differ from the two lifetime components of 25 ps and 35 ns published by Mimuro et al. (Biochim. Biophys. Acta 933 (1988) 478-486) for the D1-D2-cytochrome b-559 complex, obtained for F682 at 4 degrees C by a time-resolved photon-counting spectrofluorometer. When the reaction centers are closed by pretreatment with sodium dithionite and methyl viologen followed by exposure to laser excitation, conditions known to result in accumulation of reduced pheophytin, a dramatic decrease in the contribution of the slow lifetime component(s) is observed. These results suggest that the slow distribution lifetime component(s) in the 5-20 ns range originate(s) in the back reaction of the charge separated state. On the other hand, the fast lifetime component(s) in the picosecond range may be only partially related to the charge separation, since no dramatic change is observed upon closure of the reaction center. Perhaps, this component is related, in part, to the excitation energy migration among the various chromophores in the reaction center preparations.

Published
1990

17. Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer

Author

Ratz, L, additional, Brambillasca, C, additional, Bartke, L, additional, Huetzen, M, additional, Goergens, J, additional, Leidecker, O, additional, Jachimowicz, R, additional, van de Ven, M, additional, Proost, N, additional, Siteur, B, additional, de Korte-Grimmerink, R, additional, Bouwman, P, additional, Pulver, EM, additional, de Bruijn, R, additional, Isensee, J, additional, Hucho, T, additional, Pandey, G, additional, van Lohuizen, M, additional, Mallmann, P, additional, Reinhardt, HC, additional, Jonkers, J, additional, and Puppe, J, additional

Published
2022
Full Text
View/download PDF

19. Real-world effectiveness of reslizumab in patients with severe eosinophilic asthma – “first initiators” and “switchers”

Author

Hashimoto, S, primary, Kroes, J A, additional, Eger, K, additional, Mau-Asam, P, additional, Hofstee, H B, additional, Bendien, S A, additional, Braunstahl, G, additional, Broeders, M E, additional, Imming, L M, additional, Langeveld, B, additional, Maitland-Van Der Zee, A H, additional, Oud, K T, additional, Patberg, K W, additional, Smeenk, F W, additional, Romme, E A, additional, Van Bezouw, M J, additional, Van De Ven, M J, additional, Van Veen, A, additional, Van Velzen, E, additional, Van Veen, I H, additional, Weersink, E J, additional, Ten Brinke, A, additional, Sont, J K, additional, Bel, E H, additional, and Team, R A P S O D I, additional

Published
2022
Full Text
View/download PDF

20. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

Author

Woo, X.Y., Giordano, J., Srivastava, A., Zhao, Z.-., Lloyd, M.W., de Bruijn, R., Suh, Y.-., Patidar, R., Chen, L., Scherer, S., Bailey, M.H., Yang, C.-., Cortes-Sanchez, E., Xi, Y., Wang, J., Wickramasinghe, J., Kossenkov, A.V., Rebecca, V.W., Sun, H., Mashl, R.J., Davies, S.R., Jeon, R., Frech, C., Randjelovic, J., Rosains, J., Galimi, F., Bertotti, A., Lafferty, A., O'Farrell, A.C., Modave, E., Lambrechts, D., ter Brugge, P., Marangoni, E., El Botty, R., Kim, H., Kim, J.-., Yang, H.-., Lee, C., Dean, D.A., Davis-Dusenbery, B., Evrard, Y.A., Doroshow, J.H., Welm, A.L., Welm, B.E., Lewis, M.T., Fang, B., Roth, J.A., Meric-Bernstam, F., Herlyn, M., Davies, M.A., Ding, L., Li, S., Govindan, R., Isella, C., Moscow, J.A., Trusolino, L., Byrne, A.T., Jonkers, J., Bult, C.J., Medico, E., Chuang, J.H., Robinson, P.N., Sanderson, B.J., Neuhauser, S.B., Dobrolecki, L.E., Zheng, X., Majidi, M., Zhang, R., Zhang, X., Akcakanat, A., Evans, K.W., Yap, T.A., Li, D., Yucan, E., Lanier, C.D., Saridogan, T., Kirby, B.P., M. J., H., Chen, H., Kopetz, S., Menter, D.G., Zhang, J., Westin, S.N., Kim, M.P., Dai, B., Gibbons, D.L., Tapia, C., Jensen, V.B., Boning, G., Minna, J.D., Park, H., Timmons, B.C., Girard, L., Fingerman, D., Liu, Q., Somasundaram, R., Xiao, M., Yennu-Nanda, V.G., Tetzlaff, M.T., Xu, X., Nathanson, K.L., Cao, S., Chen, F., Dipersio, J.F., Lim, K.H., C. X., M., Rodriguez, F.M., Van Tine, B.A., Wang-Gillam, A., Wendl, M.C., Wu, Y., Wyczalkowski, M.A., Yao, L., Jayasinghe, R., Aft, R.L., Fields, R.C., Luo, J., Fuh, K.C., Chin, V., Digiovanna, J., Grover, J., Koc, S., Seepo, S., Wallace, T., Pan, C.-., Chen, M.S., Carvajal-Carmona, L.G., Kirane, A.R., Cho, M., Gandara, D.R., Riess, J.W., Le, T., deVere White, R.W., Tepper, C.G., Zhang, H., Coggins, N.B., Lott, P., Estrada, A., Toal, T., Arana, A.M., Polanco-Echeverry, G., Rocha, S., A. -H., M., Mitsiades, N., Kaochar, S., O'Malley, B.W., Ellis, M.J., Hilsenbeck, S.G., Ittmann, M., Corso, S., Fiori, A., Giordano, S., van de Ven, M., Peeper, D.S., Miller, I., Bernado, C., Morancho, B., Ramirez, L., Arribas, J., Palmer, H.G., Piris-Gimenez, A., Soucek, L., Dahmani, A., Montaudon, E., Nemati, F., Dangles-Marie, V., Decaudin, D., Roman-Roman, S., Alferez, D.G., Spence, K., Clarke, R.B., Bentires-Alj, M., Chang, D.K., Biankin, A.V., Bruna, A., O'Reilly, M., Caldas, C., Casanovas, O., Gonzalez-Suarez, E., Munoz, P., Villanueva, A., Conte, N., Mason, J., Thorne, R., Meehan, T.F., Parkinson, H., Dudova, Z., Krenek, A., Stuchlik, D., Elemento, O., Inghirami, G., Golebiewska, A., Niclou, S.P., Wisman, G.B.A., de Jong, S., Kralova, P., Sedlacek, R., Claeys, E., Leucci, E., Borsani, M., Lanfrancone, L., Pelicci, P.G., Maelandsmo, G.M., Norum, J.H., Vinolo, E., Serra, V., and Leucci, Eleonora

Subjects
endocrine system diseases, Microarray, gene amplification, Whole Exome Sequencing, Mice, 0302 clinical medicine, Gene expression, Databases, Genetic, Gene duplication, Neoplasm Metastasis, Exome sequencing, Cancer, Regulation of gene expression, 0303 health sciences, Manchester Cancer Research Centre, adult, adult, animal experiment, animal model, animal tissue, breast cancer, microarray, DNA sequencing engraftment, gene amplification, tumor, xenograft, tumor-related gene, Polymorphism, Single Nucleotide/genetics, 3. Good health, Gene Expression Regulation, Neoplastic, 030220 oncology & carcinogenesis, microarray, hormones, hormone substitutes, and hormone antagonists, tumor, endocrine system, DNA sequencing engraftment, animal experiment, DNA Copy Number Variations/genetics, Biology, digestive system, DNA sequencing, Article, animal tissue, 03 medical and health sciences, breast cancer, Breast cancer, Genetics, medicine, Animals, Humans, xenograft, Gene, 030304 developmental biology, Settore MED/04 - Patologia Generale, Microarray analysis techniques, animal model, ResearchInstitutes_Networks_Beacons/mcrc, tumor-related gene, medicine.disease, Xenograft Model Antitumor Assays, Computational biology and bioinformatics, Cancer research, Human cancer
Abstract

Patient-derived xenografts (PDXs) are resected human tumors engrafted into mice for preclinical studies and therapeutic testing. It has been proposed that the mouse host affects tumor evolution during PDX engraftment and propagation, affecting the accuracy of PDX modeling of human cancer. Here, we exhaustively analyze copy number alterations (CNAs) in 1,451 PDX and matched patient tumor (PT) samples from 509 PDX models. CNA inferences based on DNA sequencing and microarray data displayed substantially higher resolution and dynamic range than gene expression-based inferences, and they also showed strong CNA conservation from PTs through late-passage PDXs. CNA recurrence analysis of 130 colorectal and breast PT/PDX-early/PDX-late trios confirmed high-resolution CNA retention. We observed no significant enrichment of cancer-related genes in PDX-specific CNAs across models. Moreover, CNA differences between patient and PDX tumors were comparable to variations in multiregion samples within patients. Our study demonstrates the lack of systematic copy number evolution driven by the PDX mouse host., Analysis of copy number alterations in 1,451 patient-derived xenografts (PDXs) and matched patient tumor samples shows strong conservation from patient tumors through late-passage PDXs and a lack of systematic copy number evolution driven by the mouse host.

Published
2021
Full Text
View/download PDF

21. Developing a dynamic simulation model to support the nationwide implementation of whole genome sequencing in lung cancer

Author

van de Ven, M, IJzerman, M, Retel, V, van Harten, W, Koffijberg, H, van de Ven, M, IJzerman, M, Retel, V, van Harten, W, and Koffijberg, H

Abstract

BACKGROUND: This study shows how dynamic simulation modeling can be applied in the context of the nationwide implementation of Whole Genome Sequencing (WGS) for non-small cell lung cancer (NSCLC) to inform organizational decisions regarding the use of complex and disruptive health technologies and how these decisions affect their potential value. METHODS: Using the case of the nationwide implementation of WGS into clinical practice in lung cancer in the Dutch healthcare system, we developed a simulation model to show that including service delivery features across the diagnostic pathway can provide essential insight into the affordability and accessibility of care at the systems level. The model was implemented as a hybrid Agent-Based Model and Discrete-Event Simulation model in AnyLogic and included 78 hospital agents, 7 molecular tumor board agents, 1 WGS facility agent, and 5313 patient agents each year in simulation time. RESULTS: The model included patient and provider heterogeneity, including referral patterns, capacity constraints, and diagnostic workflows. Patient preference and adoption by healthcare professionals were also modeled. The model was used to analyze a scenario in which only academic hospitals have implemented WGS. To prevent delays in the diagnostic pathway, the capacity to sequence at least 1600 biopsies yearly should be present. There is a two-fold increase in mean diagnostic pathway duration between no patients referred or all patients referred for further diagnostics. CONCLUSIONS: The systems model can complement conventional health economic evaluations to investigate how the organization of the workflow can influence the actual use and impact of WGS. Insufficient capacity to provide WGS and referral patterns can substantially impact the duration of the diagnostic pathway and thus should be considered in the implementation of WGS.

Published
2022

22. Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer

Author

Ratz, L., Brambillasca, C., Bartke, L., Huetzen, M., Goergens, J., Leidecker, O., Jachimowicz, R., van de Ven, M., Proost, N., Siteur, B., de Korte-Grimmerink, R., Bouwman, P., Pulver, E. M., de Bruijn, R., Isensee, J., Hucho, T., Pandey, G., van Lohuizen, M., Mallmann, P., Reinhardt, H. C., Jonkers, J., Puppe, J., Ratz, L., Brambillasca, C., Bartke, L., Huetzen, M., Goergens, J., Leidecker, O., Jachimowicz, R., van de Ven, M., Proost, N., Siteur, B., de Korte-Grimmerink, R., Bouwman, P., Pulver, E. M., de Bruijn, R., Isensee, J., Hucho, T., Pandey, G., van Lohuizen, M., Mallmann, P., Reinhardt, H. C., Jonkers, J., and Puppe, J.

Published
2022

23. Vasogenic Oedema and Brain Infarction in an Experimental Penumbra Model

Author

Haseldonckx, M., van Bedaf, D., van de Ven, M., van Reempts, J., Borgers, M., Reulen, H.-J., editor, Steiger, H.-J., editor, Mendelow, A. David, editor, Baethmann, Alexander, editor, Czernicki, Zbigniew, editor, Hoff, Julian T., editor, Ito, Umeo, editor, James, Hector E., editor, Kuroiwa, Toshihika, editor, Marmarou, Anthony, editor, Marshall, Lawrence F., editor, and Reulen, Hans-Jürgen, editor

Published
2000
Full Text
View/download PDF

28. Real-World Utilization of Biomarker Testing for Patients with Advanced Non-Small Cell Lung Cancer in a Tertiary Referral Center and Referring Hospitals

Author

van de Ven, M, Koffijberg, H, Retel, V, Monkhorst, K, Smit, E, van Harten, W, IJzerman, M, van de Ven, M, Koffijberg, H, Retel, V, Monkhorst, K, Smit, E, van Harten, W, and IJzerman, M

Abstract

The continued introduction of biomarkers and innovative testing methods makes already complex diagnosis in patients with stage IV non-small-cell lung cancer (NSCLC) even more complex. This study primarily analyzed variations in biomarker testing in clinical practice in patients referred to a comprehensive cancer center in the Netherlands. The secondary aim was to compare the cost of biomarker testing with the cost of whole-genome sequencing. The cohort included 102 stage IV NSCLC patients who received biomarker testing in 2017 or 2018 at the comprehensive cancer center. The complete biomarker testing history of the cohort was identified using linked data from the comprehensive cancer center and the nationwide network and registry of histopathology and cytopathology in the Netherlands. Unique biomarker-test combinations, costs, turnaround times, and test utilization were examined. The results indicate substantial variation in test utilization and sequences. The mean cost per patient of biomarker testing was 2259.92 ± 1217.10 USD, or 1881.23 ± 1013.15 EUR. Targeted gene panels were most frequently conducted, followed by IHC analysis for programmed cell death protein ligand 1. Typically, the most common biomarkers were assessed within the first tests, and emerging biomarkers were tested further down the test sequence. At the cost of current biomarker testing, replacing current testing with whole-genome sequencing would have led to cost-savings in only two patients (2%).

Published
2021

29. Whole genome sequencing in oncology: using scenario drafting to explore future developments

Author

van de Ven, M, Simons, MJHG, Koffijberg, H, Joore, MA, IJzerman, MJ, Retel, VP, van Harten, WH, van de Ven, M, Simons, MJHG, Koffijberg, H, Joore, MA, IJzerman, MJ, Retel, VP, and van Harten, WH

Abstract

BACKGROUND: In oncology, Whole Genome Sequencing (WGS) is not yet widely implemented due to uncertainties such as the required infrastructure and expertise, costs and reimbursements, and unknown pan-cancer clinical utility. Therefore, this study aimed to investigate possible future developments facilitating or impeding the use of WGS as a molecular diagnostic in oncology through scenario drafting. METHODS: A four-step process was adopted for scenario drafting. First, the literature was searched for barriers and facilitators related to the implementation of WGS. Second, they were prioritized by international experts, and third, combined into coherent scenarios. Fourth, the scenarios were implemented in an online survey and their likelihood of taking place within 5 years was elicited from another group of experts. Based on the minimum, maximum, and most likely (mode) parameters, individual Program Evaluation and Review Technique (PERT) probability density functions were determined. Subsequently, individual opinions were aggregated by performing unweighted linear pooling, from which summary statistics were extracted and reported. RESULTS: Sixty-two unique barriers and facilitators were extracted from 70 articles. Price, clinical utility, and turnaround time of WGS were ranked as the most important aspects. Nine scenarios were developed and scored on likelihood by 18 experts. The scenario about introducing WGS as a clinical diagnostic with a lower price, shorter turnaround time, and improved degree of actionability, scored the highest likelihood (median: 68.3%). Scenarios with low likelihoods and strong consensus were about better treatment responses to more actionable targets (26.1%), and the effect of centralizing WGS (24.1%). CONCLUSIONS: Based on current expert opinions, the implementation of WGS as a clinical diagnostic in oncology is heavily dependent on the price, clinical utility (both in terms of identifying actionable targets as in adding sufficient value in s

Published
2021

30. Females with cystic fibrosis have a larger decrease in sweat chloride in response to lumacaftor/ivacaftor compared to males

Author

Onderzoek Longziekten, Infection & Immunity, Longziekten, Longziekten patientenzorg, Child Health, Verpleegkundig Specialisten Longziekten, Speerpunt Child Health, Aalbers, B. L., Hofland, R. W., Bronsveld, I., de Winter-de Groot, K. M., Arets, H. G.M., de Kiviet, A. C., van Oirschot-van de Ven, M. M.M., Kruijswijk, M. A., Schotman, S., Michel, S., van der Ent, C. K., Heijerman, H. G.M., Onderzoek Longziekten, Infection & Immunity, Longziekten, Longziekten patientenzorg, Child Health, Verpleegkundig Specialisten Longziekten, Speerpunt Child Health, Aalbers, B. L., Hofland, R. W., Bronsveld, I., de Winter-de Groot, K. M., Arets, H. G.M., de Kiviet, A. C., van Oirschot-van de Ven, M. M.M., Kruijswijk, M. A., Schotman, S., Michel, S., van der Ent, C. K., and Heijerman, H. G.M.

Published
2021

35. BRCA1 and BRCA2 are epistatic in mammary tumorigenesis and drug response

Author

Puppe, J, additional, Liu, X, additional, van de Ven, M, additional, Ratz, L, additional, Bartke, L, additional, van Vliet, M, additional, Wientjes, E, additional, van der Gulden, H, additional, Zevenhoven, J, additional, Malter, W, additional, Song, JY, additional, Wessels, LFA, additional, Hahnen, E, additional, Reinhardt, HC, additional, Mallmann, P, additional, Schmutzler, R, additional, Linn, S, additional, and Jonkers, J, additional

Published
2021
Full Text
View/download PDF

36. EZH2 inhibition sensitizes BRCA1-deficient breast cancer cells to synthetic lethal therapy with ATM inhibitors

Author

Ratz, L, additional, Brambillasca, C, additional, Bartke, L, additional, van de Ven, M, additional, Bouwman, P, additional, van Tellingen, O, additional, Isensee, J, additional, Hucho, T, additional, Pandey, G, additional, van Lohuizen, M, additional, Mallmann, P, additional, Jonkers, J, additional, Reinhardt, HC, additional, and Pupp, J, additional

Published
2021
Full Text
View/download PDF

37. Cellular Radiosensitivity of Soft Tissue Sarcoma

Author

Haas, R. L., primary, Floot, B. G. J., additional, Scholten, A. N., additional, van der Graaf, W. T. A., additional, van Houdt, W., additional, Schrage, Y., additional, van de Ven, M., additional, Bovée, J. V. M. G., additional, van Coevorden, F., additional, and Vens, C., additional

Published
2021
Full Text
View/download PDF

38. Rekenmethode risico's doorgaand vervoer gevaarlijke stoffen over spoor : Een actualisatie op basis van grote ongevallen in Europa

Author

Uijt de Haag, PAM, Bos, HG, Schulenberg, AJH, Timmers, PGJ, and van de Ven, M

Subjects
RIVM rapport 2019-0208
Abstract

Dit rapport bevat een addendum d.d. 02-02-2022 op pagina 35. Dit rapport bevat een bijlage: RIVM-rapport 2019-0209 bijlage Sommige grondstoffen en producten in de chemische industrie zijn brandbaar of giftig. Vervoer over het spoor van en naar de chemische industrie brengt risico's met zich mee voor de omgeving. In het Nederlandse beleid voor veilig vervoer van gevaarlijke stoffen en omgevingsveiligheid wordt gebruikgemaakt van een rekenmethode om de risico's voor de omgeving in te schatten. De huidige methode is gemaakt in de jaren negentig van de vorige eeuw. Het RIVM heeft de rekenmethode geactualiseerd. Het RIVM heeft voor dit onderzoek grote ongevallen in de afgelopen dertig jaar in Europa verzameld, geanalyseerd en vertaald naar de Nederlandse situatie. Op basis daarvan zijn kansen op een groot ongeval en de effecten daarvan bijgewerkt. Met de aangepaste methode worden de risico's berekend op basis van recente ongevalsgegevens. Het RIVM adviseert het Ministerie van Infrastructuur en Waterstaat daarom om de aangepaste rekenmethode te gebruiken in het beleid voor veilig vervoer van gevaarlijke stoffen en omgevingsveiligheid. Het RIVM heeft dit onderzoek gedaan in samenwerking met adviesbureau AVIV. Zij betrokken daarbij een aantal deskundigen van adviesbureaus, bedrijven, omgevingsdiensten en ProRail.

Published
2020

39. The Fornax Deep Survey with VST

Author

M. A. Raj, E. Iodice, N. R. Napolitano, M. Hilker, M. Spavone, R. F. Peletier, H-S. Su, J. Falcón-Barroso, G. van de Ven, M. Cantiello, D. Kleiner, A. Venhola, S. Mieske, M. Paolillo, M. Capaccioli, P. Schipani

Published
2020
Full Text
View/download PDF

40. Dual inhibition of EZH2 and ATM displays synergistic cytotoxicity in BRCA1-deficient breast

Author

Puppe, J., Brambillasca, C., Ratz, L., Bartke, L., van de Ven, M., Bouwman, P., van Tellingen, O., Isensee, J., Hucho, T., van Lohuizen, M., Malter, W., Schmutzler, R., Mallmann, P., Jonkers, J., Reinhardt, C., Puppe, J., Brambillasca, C., Ratz, L., Bartke, L., van de Ven, M., Bouwman, P., van Tellingen, O., Isensee, J., Hucho, T., van Lohuizen, M., Malter, W., Schmutzler, R., Mallmann, P., Jonkers, J., and Reinhardt, C.

Published
2020

41. Double BRCA1 and BRCA2 inactivation is epistatic in mammary tumorigenesis and treatment response to PARP-inhibition and platinum drugs

Author

Puppe, J., Liu, X., Ratz, L., Bartke, L., van de Ven, M., Vliet, M. H., Wientjes, E., van der Gulden, H., Zevenhoven, J., Hahnen, E., Malter, W., Wessels, L. F. A., Schmutzler, R., Mallmann, P., Reinhardt, C., Linn, S., Jonkers, J., Puppe, J., Liu, X., Ratz, L., Bartke, L., van de Ven, M., Vliet, M. H., Wientjes, E., van der Gulden, H., Zevenhoven, J., Hahnen, E., Malter, W., Wessels, L. F. A., Schmutzler, R., Mallmann, P., Reinhardt, C., Linn, S., and Jonkers, J.

Published
2020

42. Characteristics and treatment regimens across ERS SHARP severe asthma registries

Author

van Bragt, JJMH, Adcock, IM, Bel, EHD, Braunstahl, G-J, ten Brinke, A, Busby, J, Canonica, GW, Cao, H, Chung, KF, Csoma, Z, Dahlen, B, Davin, E, Hansen, S, Heffler, E, Horvath, I, Korn, S, Kots, M, Kuna, P, Kwon, N, Louis, R, Plaza, V, Porsbjerg, C, Ramos-Barbon, D, Richards, LB, Skrgat, S, Sont, JK, Vijverberg, SJH, Weersink, EJM, Yasinska, V, Wagers, SS, Djukanovic, R, Maitland-van der Zee, AH, Abenhardt, B, Adler, J, Alfonso, R, Ali, R, Alkameh, S, Almonacid Sanchez, C, Alvares, L, Anderson, G, Assing, K, Ayre, S, Becker, J, Bergmann, K, Bieksiene, K, Bjerring, N, Blasi, F, Bloemen, P, Blum, H, Boeing, S, Bonavia, M, Bossios, A, Bourdin, A, Brons, A, Brusselle, G, Buis, J, Caiaffa, M, Calabrese, C, Camiciottoli, G, Caruso, C, Castilla Martinez, M, Centanni, S, Cisneros Serrano, C, Corsico, A, Cosmi, L, Costantino, M, Costello, R, Crimi, N, Dahlen, S, D'Amato, M, Davies, D, Garcia-Cosio Piqueras, FDB, Decarlo, G, Deimling, A, Del Giacco, S, Diaz Campos, R, Djandji, M, Doberer, D, Dupont, L, Dyett, K, Edelbaher, N, Edelmann, M, Ehmann, R, Ekberg-Jansson, A, Farsi, A, Favero, E, Feimer, J, Fletcher, M, Foschino, B, Frankemolle, B, Gaga, M, Gappa, M, Garcia de Pedro, J, Garcia Rivero, J, Gasplmayr, M, Gebhardt, R, Geldmacher, H, Geltner, C, Gerstlauer, M, Gibson, T, Giuseppe, G, Gogoll, C, Grimm-Sachs, V, Grisle, I, Gruen, B, Gruenewaldt, A, Guarnieri, G, Gullon Blanco, J, Hamelmann, E, Hamerlijnck, D, Hammers-Reinhard, A, Hanon, S, Harzheim, D, Heaney, L, Hellmich, S, Herden, M, Hering, T, Herth, F, Hilberg, O, Howarth, P, Hubatsch, M, Humbert, M, Husemann, K, Idzko, M, Jackson, D, Jandl, M, Jaumont, X, Joos, G, Joest, M, Juech, M, Kabesch, M, Kaiser-Labusch, P, Kardos, P, Kaessner, F, Keeley, T, Kerr, W, Kirschner, J, Klimek, L, Koca, M, Koczulla, R, Koerner-Rettberg, C, Kopac, P, Kronsbein, J, Lipinska, IK, Langer, M, Langeveld, B, Lantz, A, Lazarinis, N, Lazic, Z, Lehtimaki, L, Leuppi, J, Lombardi, C, Lommatzsch, M, Lopez-Vina, A, Luca, R, Ludviksdottir, D, Luettecke-Hecht, C, Macchia, L, Magni, T, Martinez Rivera, C, Mastoridis, P, Mazza, F, Menzella, F, Menzies-Gow, A, Michils, A, Mihaltan, F, Milanese, M, Milger-Kneidinger, K, Molinska, J, Montagna, I, Montuschi, P, Muelleneisen, N, Munoz Esquerre, M, Nanzer-Kelly, A, Nenasheva, N, Neurohr, C, Nucera, E, Otker, J, Oud, K, Paggiaro, P, Parente, R, Parkinson, J, Passalacqua, G, Patberg, N, Patella, V, Patino, O, Paulsson, T, Peche, R, Pelaia, G, Peress, E, Perez de Llano, L, Pfeffer, P, Pfister, P, Pilette, C, Pinedo Sierra, C, Pini, L, Powitz, F, Ranger, T, Rasmussen, L, Rasmussen, K, Rezelj, M, Ricciardi, L, Ricciardolo, F, Ridolo, E, Rijssenbeek-Nouwens, L, Rolla, G, Romero Ribate, D, Ruediger, S, Safioti, G, Sandstrom, T, Santus, P, Sauer, R, Schauerte, G, Schipmann, R, Schleich, F, Schmid, J, Schmidt, F, Schmidt, O, Schmitz, M, Schrag, T, Schroeer, S, Schultz, K, Schulz, C, Scichilone, N, Sedlak, V, Selb, J, Senna, G, Sergejeva, S, Serrano Pariente, J, Sichau, M, Simona, D, Singer, A, Skowasch, D, Smeenk, F, Smith, S, Solidoro, P, Spadaro, G, Spanevello, A, Stefansdottir, M, Steinmetz, K, Steiss, J, Stephan, M, Stieglitz, S, Suhling, H, Taube, C, Yavuz, ST, Tudoric, N, Ulrik, C, van de Ven, M, van den Elshout, F, Van Dyke, M, Van Nederveen-Bendien, S, van Veen, I, Vandenplas, O, Velthove, K, Vianello, A, Vogelberg, C, Wallen-Nielsen, E, Weersink, EJ, Wisskirchen, T, Yacoub, M, Yancey, S, Zappa, M, Zielen, S, Zimmermann, C, Zimmermann, R, van Bragt, JJMH, Adcock, IM, Bel, EHD, Braunstahl, G-J, ten Brinke, A, Busby, J, Canonica, GW, Cao, H, Chung, KF, Csoma, Z, Dahlen, B, Davin, E, Hansen, S, Heffler, E, Horvath, I, Korn, S, Kots, M, Kuna, P, Kwon, N, Louis, R, Plaza, V, Porsbjerg, C, Ramos-Barbon, D, Richards, LB, Skrgat, S, Sont, JK, Vijverberg, SJH, Weersink, EJM, Yasinska, V, Wagers, SS, Djukanovic, R, Maitland-van der Zee, AH, Abenhardt, B, Adler, J, Alfonso, R, Ali, R, Alkameh, S, Almonacid Sanchez, C, Alvares, L, Anderson, G, Assing, K, Ayre, S, Becker, J, Bergmann, K, Bieksiene, K, Bjerring, N, Blasi, F, Bloemen, P, Blum, H, Boeing, S, Bonavia, M, Bossios, A, Bourdin, A, Brons, A, Brusselle, G, Buis, J, Caiaffa, M, Calabrese, C, Camiciottoli, G, Caruso, C, Castilla Martinez, M, Centanni, S, Cisneros Serrano, C, Corsico, A, Cosmi, L, Costantino, M, Costello, R, Crimi, N, Dahlen, S, D'Amato, M, Davies, D, Garcia-Cosio Piqueras, FDB, Decarlo, G, Deimling, A, Del Giacco, S, Diaz Campos, R, Djandji, M, Doberer, D, Dupont, L, Dyett, K, Edelbaher, N, Edelmann, M, Ehmann, R, Ekberg-Jansson, A, Farsi, A, Favero, E, Feimer, J, Fletcher, M, Foschino, B, Frankemolle, B, Gaga, M, Gappa, M, Garcia de Pedro, J, Garcia Rivero, J, Gasplmayr, M, Gebhardt, R, Geldmacher, H, Geltner, C, Gerstlauer, M, Gibson, T, Giuseppe, G, Gogoll, C, Grimm-Sachs, V, Grisle, I, Gruen, B, Gruenewaldt, A, Guarnieri, G, Gullon Blanco, J, Hamelmann, E, Hamerlijnck, D, Hammers-Reinhard, A, Hanon, S, Harzheim, D, Heaney, L, Hellmich, S, Herden, M, Hering, T, Herth, F, Hilberg, O, Howarth, P, Hubatsch, M, Humbert, M, Husemann, K, Idzko, M, Jackson, D, Jandl, M, Jaumont, X, Joos, G, Joest, M, Juech, M, Kabesch, M, Kaiser-Labusch, P, Kardos, P, Kaessner, F, Keeley, T, Kerr, W, Kirschner, J, Klimek, L, Koca, M, Koczulla, R, Koerner-Rettberg, C, Kopac, P, Kronsbein, J, Lipinska, IK, Langer, M, Langeveld, B, Lantz, A, Lazarinis, N, Lazic, Z, Lehtimaki, L, Leuppi, J, Lombardi, C, Lommatzsch, M, Lopez-Vina, A, Luca, R, Ludviksdottir, D, Luettecke-Hecht, C, Macchia, L, Magni, T, Martinez Rivera, C, Mastoridis, P, Mazza, F, Menzella, F, Menzies-Gow, A, Michils, A, Mihaltan, F, Milanese, M, Milger-Kneidinger, K, Molinska, J, Montagna, I, Montuschi, P, Muelleneisen, N, Munoz Esquerre, M, Nanzer-Kelly, A, Nenasheva, N, Neurohr, C, Nucera, E, Otker, J, Oud, K, Paggiaro, P, Parente, R, Parkinson, J, Passalacqua, G, Patberg, N, Patella, V, Patino, O, Paulsson, T, Peche, R, Pelaia, G, Peress, E, Perez de Llano, L, Pfeffer, P, Pfister, P, Pilette, C, Pinedo Sierra, C, Pini, L, Powitz, F, Ranger, T, Rasmussen, L, Rasmussen, K, Rezelj, M, Ricciardi, L, Ricciardolo, F, Ridolo, E, Rijssenbeek-Nouwens, L, Rolla, G, Romero Ribate, D, Ruediger, S, Safioti, G, Sandstrom, T, Santus, P, Sauer, R, Schauerte, G, Schipmann, R, Schleich, F, Schmid, J, Schmidt, F, Schmidt, O, Schmitz, M, Schrag, T, Schroeer, S, Schultz, K, Schulz, C, Scichilone, N, Sedlak, V, Selb, J, Senna, G, Sergejeva, S, Serrano Pariente, J, Sichau, M, Simona, D, Singer, A, Skowasch, D, Smeenk, F, Smith, S, Solidoro, P, Spadaro, G, Spanevello, A, Stefansdottir, M, Steinmetz, K, Steiss, J, Stephan, M, Stieglitz, S, Suhling, H, Taube, C, Yavuz, ST, Tudoric, N, Ulrik, C, van de Ven, M, van den Elshout, F, Van Dyke, M, Van Nederveen-Bendien, S, van Veen, I, Vandenplas, O, Velthove, K, Vianello, A, Vogelberg, C, Wallen-Nielsen, E, Weersink, EJ, Wisskirchen, T, Yacoub, M, Yancey, S, Zappa, M, Zielen, S, Zimmermann, C, and Zimmermann, R

Abstract

Little is known about the characteristics and treatments of patients with severe asthma across Europe, but both are likely to vary. This is the first study in the European Respiratory Society Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) Clinical Research Collaboration and it is designed to explore these variations. Therefore, we aimed to compare characteristics of patients in European severe asthma registries and treatments before starting biologicals.This was a cross-sectional retrospective analysis of aggregated data from 11 national severe asthma registries that joined SHARP with established patient databases.Analysis of data from 3236 patients showed many differences in characteristics and lifestyle factors. Current smokers ranged from 0% (Poland and Sweden) to 9.5% (Belgium), mean body mass index ranged from 26.2 (Italy) to 30.6 kg·m-2 (the UK) and the largest difference in mean pre-bronchodilator forced expiratory volume in 1 s % predicted was 20.9% (the Netherlands versus Hungary). Before starting biologicals patients were treated differently between countries: mean inhaled corticosteroid dose ranged from 700 to 1335 µg·day-1 between those from Slovenia versus Poland when starting anti-interleukin (IL)-5 antibody and from 772 to 1344 µg·day-1 in those starting anti-IgE (Slovenia versus Spain). Maintenance oral corticosteroid use ranged from 21.0% (Belgium) to 63.0% (Sweden) and from 9.1% (Denmark) to 56.1% (the UK) in patients starting anti-IL-5 and anti-IgE, respectively.The severe asthmatic population in Europe is heterogeneous and differs in both clinical characteristics and treatment, often appearing not to comply with the current European Respiratory Society/American Thoracic Society guidelines definition of severe asthma. Treatment regimens before starting biologicals were different from inclusion criteria in clinical trials and varied between countries.

Published
2020

43. Clinical effect of lumacaftor/ivacaftor in F508del homozygous CF patients with FEV1 ≥ 90% predicted at baseline

Author

Onderzoek Longziekten, Infection & Immunity, Longziekten patientenzorg, Child Health, Longziekten, Verpleegkundig Specialisten Longziekten, Speerpunt Child Health, Aalbers, B L, de Winter-de Groot, K M, Arets, H G M, Hofland, R W, de Kiviet, A C, van Oirschot-van de Ven, M M M, Kruijswijk, M A, Schotman, S, Michel, S, van der Ent, C K, Heijerman, H G M, Onderzoek Longziekten, Infection & Immunity, Longziekten patientenzorg, Child Health, Longziekten, Verpleegkundig Specialisten Longziekten, Speerpunt Child Health, Aalbers, B L, de Winter-de Groot, K M, Arets, H G M, Hofland, R W, de Kiviet, A C, van Oirschot-van de Ven, M M M, Kruijswijk, M A, Schotman, S, Michel, S, van der Ent, C K, and Heijerman, H G M

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results